The dopamine agonist cabergoline has been used to treat prolactinomas, Parkinson's disease, Cushing's disease and sexual dysfunction. However, its clinical use was severely curtailed when it was found that patients taking cabergoline had an increased risk of developing cardiac-valve regurgitation. This potentially life-threatening condition has been associated with drugs, such as cabergoline, that are 5-HT receptor agonists. We prepared analogs of cabergoline and have identified several that have limited or no agonism at the 5-HT receptor.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629922 | PMC |
| http://dx.doi.org/10.1021/ml3003814 | DOI Listing |
Publication Analysis
Top Keywords
analogs cabergoline
8
5-ht receptor
8
cabergoline
5
synthesis novel
4
novel analogs
4
cabergoline improving
4
improving cardiovascular
4
cardiovascular safety
4
safety removing
4
removing 5-ht2b
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!